Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases Sep 25, 2015
RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study Sep 16, 2015
RepliCel Life Sciences Cleared to Initiate Clinical Trial of RCS-01 for Dermal Rejuvenation Sep 2, 2015
Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 ‘apabetalone’ a Selective BET Inhibitor Sep 1, 2015
Harness Biotech Volatility with an Options Strategy: Theta Strategy Capital’s Eden Rahim Aug 18, 2015
International Clinical Steering Committee Announced for Resverlogix’s Phase 3 BETonMACE Clinical Trial with RVX-208 “apabetalone” Aug 5, 2015
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink Jul 9, 2015
RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis Jul 1, 2015
RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement Jun 27, 2015
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association’s (ADA) Scientific Sessions in Boston, MA Jun 9, 2015
